Binds Drug, Hapten, Hapten--carrier Complex, Or Specifically-identified Chemical Structure (e.g., Theophylline, Digoxin, Etc.) Patents (Class 530/388.9)
-
Publication number: 20110223611Abstract: Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.Type: ApplicationFiled: March 12, 2010Publication date: September 15, 2011Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov, Howard Sard, Vishnumurthy Hegde
-
Publication number: 20110217320Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: ApplicationFiled: May 13, 2011Publication date: September 8, 2011Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20110166329Abstract: The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.Type: ApplicationFiled: October 29, 2010Publication date: July 7, 2011Inventor: Mark B. Pepys
-
Publication number: 20110165699Abstract: Novel conjugates of the pharmaceutically active metabolite of irinotecan and novel immunogens derived from this pharmaceutically active metabolite and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of the pharmaceutically active metabolite of irinotecan in biological fluids.Type: ApplicationFiled: March 3, 2011Publication date: July 7, 2011Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov, Hongxia Zhang, Howard Sard, Vishnumurthy Hegde
-
Publication number: 20110136253Abstract: Novel conjugates of the pharmaceutically active metabolite of irinotecan and novel immunogens derived from this pharmaceutically active metabolite and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of the pharmaceutically active metabolite of irinotecan in biological fluids.Type: ApplicationFiled: December 8, 2009Publication date: June 9, 2011Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Alexander Volkov, Hongxia Zhang, Howard Sard, Vishnumurthy Hegde
-
Publication number: 20110135662Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.Type: ApplicationFiled: October 27, 2010Publication date: June 9, 2011Inventors: HELENE MARGARET FINNEY, TERENCE SEWARD BAKER, ALASTAIR DAVID GRIFFITHS LAWSON, KAREN MARGRETE MILLER, MARC ROGER DE RYCK, CHRISTIAN GILBERT J. WOLFF
-
Publication number: 20110117100Abstract: Natural human autoantibodies against toxic assemblies of A? and related peptide species offer a unique immune repertoire. Based on this repertoire, the present invention provides compositions and methods for diagnosis as well as for prophylactic and therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease that are characterized by accumulation of beta-amyloid deposits. The same human autoantibodies may be useful for prophylactic and therapeutic treatment of other neurodegenerative disorders and systemic pathological conditions that are due to or are associated with toxic assemblies of other amyloidogenic peptides or proteins.Type: ApplicationFiled: November 3, 2009Publication date: May 19, 2011Applicants: The Board of Trustees of the Leland Stanford Junior University, The U.S. Government represented by the Department of Veterans AffairsInventors: Markus Britschgi, Anton Wyss-Coray
-
Patent number: 7943334Abstract: The present invention provides an immunological detection method that can detect milk allergens, allergens of albumen, flour, buckwheat and peanut with high sensitivity in foods containing these allergens regardless they are denatured/native, and a detection kit to be used therefor. It is a method for detecting allergens by using 2 or more monoclonal antibodies recognizing native and denatured milk allergens, native and denatured albumen allergens, native and denatured flour allergens, native and denatured buckwheat allergens, and native and denatured peanut allergens, using asl casein which is the main protein of milk casein, ?-lactoglobulin which is the main protein of whey, ovalubumin and ovomucoid which are main proteins of albumen, gliadin which is the main protein of flour, protein with a molecular weight of 24 kDa and 76 kDa which are main proteins of buckwheat, and Ara h1 which is the main protein of peanut as an index.Type: GrantFiled: March 4, 2005Date of Patent: May 17, 2011Assignee: Prima Meat Packers, Ltd.Inventors: Masanobu Akimoto, Shigeki Katou, Makoto Namioka
-
Publication number: 20110070247Abstract: The present invention relates to modulators of the Neuregulin (NRG) family, particularly NRG1 and more particularly NRG1?, and most particularly NRG1?1. The present invention also relates to the use of such modulators to inhibit goblet cell hyperplasia and therefore also relates to the use of such modulators in the treatment or prevention of human diseases and disorders featuring pathological mucus production such as COPD, CF, chronic bronchitis and asthma.Type: ApplicationFiled: August 22, 2008Publication date: March 24, 2011Applicant: NOVARTIS AGInventors: Carol Elizabeth Jones, Alan Jackson
-
Publication number: 20110052608Abstract: The present invention relates to a novel antibody which selectively binds to the disease associated form of prion protein (PrPSc) under native conditions and the use thereof in methods of prion disease detection, therapy and disease research in general.Type: ApplicationFiled: June 13, 2007Publication date: March 3, 2011Applicant: UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGHInventors: Mark William Head, Michael Jones
-
Patent number: 7897733Abstract: Provided are rapamycin conjugates which are useful as immunogenic molecules for the generation of antibodies specific for rapamycin, for measuring levels of rapamycin or derivatives thereof; for isolating rapamycin binding proteins; and detecting antibodies specific for rapamycin or derivatives thereof. This invention also provides a rapamycin specific monoclonal antibody.Type: GrantFiled: November 14, 2005Date of Patent: March 1, 2011Assignee: Pfizer, Inc.Inventors: Katherine L. Molnar-Kimber, Craig E. Caufield, Timothy D. Ocain
-
Patent number: 7893220Abstract: Novel conjugates of busulfan and novel busulfan immunogens derived from ?-substituted derivatives of busulfan and antibodies generated by these busulfan linked immunogens are useful in immunoassays for the quantification and monitoring of busulfan in biological fluids.Type: GrantFiled: July 9, 2008Date of Patent: February 22, 2011Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Shu He
-
Publication number: 20110020219Abstract: A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.Type: ApplicationFiled: September 17, 2008Publication date: January 27, 2011Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHEInventors: De Santis Rita, Anastasi Anna Maria
-
Publication number: 20110020363Abstract: The present invention relates generally to antibodies that bind to the Interleukin-13 receptor.alpha.1 chain (IL-13R.alpha.1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R.alpha.1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R.alpha.1/ligand interaction is also provided.Type: ApplicationFiled: July 1, 2010Publication date: January 27, 2011Applicant: ZENYTH OPERATIONS PTY LTD.Inventors: Felicity Meredith DUNLOP, Manuel BACA, Andrew Donald NASH, Louis Jerry FABRI, Douglas James HILTON, Nicos A. NICOLA
-
Patent number: 7868142Abstract: It is intended to provide an anti-photocrosslinking group antibody capable of specifically binding to a photocrosslinking group and available in the binding of a substrate and a substance of interest in a microstructure, a complex protein including at least the antibody or at least a portion thereof, and a technique for use thereof in the detection of a target substance. The present invention provides a protein having at least the structure of an antibody that recognizes a photocrosslinking group.Type: GrantFiled: October 9, 2007Date of Patent: January 11, 2011Assignee: Canon Kabushiki KaishaInventors: Satoru Hatakeyama, Takeshi Imamura, Hidenori Shiotsuka
-
Publication number: 20110003314Abstract: The invention teaches derivatives of ascomycin and methods of preparing immunogens and other conjugates useful in immunoassays for quantitatively measuring concentrations of tacrolimus in patient specimens. Antibodies produced from the disclosed immunogens capable of binding to tacrolimus with cross-reactivity of no more than 5% with each of 15-O-demethyl tacrolimus, 31-O-demethyl tacrolimus, and 13,31-O-didemethyl tacrolimus, less than 40% with 13-O-demethyl tacrolimus, and less than 1% with cyclosporin, rapamycin, mycophenolic acid, prednisone, hydrocortisol, and prednisolone are described. Further, immunoassays for measuring the concentration of tacrolimus using such antibodies are taught.Type: ApplicationFiled: September 7, 2010Publication date: January 6, 2011Applicant: MICROGENICS CORPORATIONInventors: Vani Bodepudi, Lisa Charters, Rueyming Loor
-
Publication number: 20100310597Abstract: A method that accurately and conveniently detects a compound shown by the formula (I) in a human sample is disclosed. An antibody that reacts with the compound shown by the formula (I), but does not cross-react with the N-oxide metabolite and the desmethyl levofloxacin metabolite of the compound shown by the formula (I) is prepared using an antigen produced by binding bovine serum albumin to the compound shown by the formula (I) through the 6-position carboxyl group. Immunoassay that measures the compound shown by the formula (I) that has not been metabolized is implemented using the above antibody.Type: ApplicationFiled: December 15, 2008Publication date: December 9, 2010Inventor: Osamu Miyazaki
-
Publication number: 20100310557Abstract: Antibodies which specifically bind heregulin-coupled HER3, at a site distinct from the heregulin binding site, are described. These antibodies are particularly useful in treating cancer.Type: ApplicationFiled: April 29, 2010Publication date: December 9, 2010Inventors: Bruce KEYT, Lawrence M. KAUVAR, Ellen J. COLLARINI, Orit FOORD, Gizette SPERINDE, Marjan FATHOLAHI, Hung NGUYEN
-
Publication number: 20100273193Abstract: This disclosure is drawn to a triacetone triperoxide derivative in accordance with the general formula (I) and a diacetone diperoxide derivative in accordance with the general formula (II) wherein R1 is a hydrogen residue or an optionally halogenated or perhalogenated C1 to C5 alkyl group, R2 represents a linker molecule, and X represents a reactive or activatable group. A method for the preparation of the TATP or DADP derivatives and the use thereof as antigen for the preparation of TATP- or DADP-specific antibodies or other binders is also disclosed. The antibodies are preferably used in a biosensor for the detection of TATP or DADP in air.Type: ApplicationFiled: April 26, 2010Publication date: October 28, 2010Applicant: BAM Bundesanstalt fur Materialforschung und-pruefungInventors: Astrid Walter, Rudolf J. Schneider, Michael G. Weller
-
Publication number: 20100266619Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.Type: ApplicationFiled: June 28, 2010Publication date: October 21, 2010Inventor: Greg Elson
-
Publication number: 20100233188Abstract: The present invention relates to a compound having the general Formula (I): wherein: m and n are each independently an integer from 1 to 6; X1-X3 and Y1-Y3 are each independently O or S; R1-R3 are each independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl; and R is (CH2)x—C(?O)NR?—(CH2)y—NR?R? whereas: x and y are each independently an integer from 1 to 6; and R? and R? are each independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl; and to an antibody comprising an antigen recognition region capable of specifically binding the above compound.Type: ApplicationFiled: February 21, 2008Publication date: September 16, 2010Inventors: Irit Sagi, Tamar Danon, Netta Sela, Abraham Shanzer, Rina Arad-Yellin, Raghavendra Kikkeri
-
Patent number: 7790162Abstract: The present invention discloses antibodies, antigen binding fragments, peptides and peptidomimetics immunoreactive with provasopressin and compositions thereof, methods of phenotyping tissue samples, methods of treating cancer, and kits for phenotyping test biopsy samples and bodily fluids for breast cancer, small cell lung cancer, ductal carcinoma in situ, and atypical ductal hyperplasia.Type: GrantFiled: July 16, 2003Date of Patent: September 7, 2010Assignee: Woomera Therapeutics, Inc.Inventors: William G. North, Brendan P. Keegan, Lyn Oligino
-
Patent number: 7786273Abstract: The present invention provides macromolecules comprising at least one thioether cross-link. A thioether cross-link comprising a single thioether bond between two residues of a macromolecule. The macromolecules of the invention can display enhanced stability, pharmaceutical properties and functional properties. In particular, the invention provides an isolated antibodies comprising at least one thioether cross-link that specifically bind to particular antigens. The present invention also provides a composition comprising a macromolecule substantially free of a denaturing reagent, wherein the macromolecule comprises at least one thioether cross-link. In addition, the present invention provides a method for producing the macromolecules and compositions of the invention.Type: GrantFiled: March 14, 2006Date of Patent: August 31, 2010Assignee: Medimmune, LLCInventors: Guillermo I. Tous, Mark Schenerman, Ziping Wei
-
Publication number: 20100209416Abstract: Generally, the present invention relates to lamotrigine analogs that have substituents at the triazine 3-position and on the benzene 4-position and 5-position. The lamotrigine analogs can include immunogenic moieties that can be used to prepare anti-lamotrigine antibodies, or antigenic moieties that can be used in immunodiagnostic assays for lamotrigine. Also, the lamotrigine analog can include tracer moieties for detecting the presence or amount of the analog during an immunodiagnostic assay. Additionally, the lamotrigine analogs can be used in immunodiagnostic assays to compete with lamotrigine for binding with anti-lamotrigine antibodies.Type: ApplicationFiled: January 25, 2010Publication date: August 19, 2010Applicant: Serydyn, Inc.Inventors: Anlong Ouyang, Lili Arabshahi, Mark Roberts, Melissa Wall
-
Publication number: 20100204456Abstract: Novel conjugates of 5-fluoro-uracil and novel 5-fluoro-uracil immunogens and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of 5-fluoro-uracil in biological fluids.Type: ApplicationFiled: April 26, 2010Publication date: August 12, 2010Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Dennis Stocker
-
Patent number: 7767794Abstract: Novel conjugates of 5-fluoro-uracil and novel 5-fluoro-uracil immunogens and monoclonal antibodies generated by these immunogens which are useful in immunoassays for the quantification and monitoring of 5-fluoro-uracil in biological fluids.Type: GrantFiled: February 20, 2007Date of Patent: August 3, 2010Assignee: Saladax Biomedical IncInventors: Salvatore J. Salamone, Jodi Blake Courtney, Dennis Stocker
-
Publication number: 20100173427Abstract: Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.Type: ApplicationFiled: October 22, 2009Publication date: July 8, 2010Inventors: Johnny Jose Valdez, Byung Sook Moon, Ki Chung, Alejandro A. Orozco
-
Patent number: 7749502Abstract: The present invention relates to an oral composition and an immunogenic composition for the suppression of the pathogenic effects of the intra-oral bacterium Porphyromonas gingivalis associated with periodontal disease.Type: GrantFiled: March 30, 2007Date of Patent: July 6, 2010Assignee: The University of MelbourneInventors: Eric C. Reynolds, Neil Martin O'Brien-Simpson, Nada Slakeski
-
Patent number: 7745589Abstract: Unnatural substrates of prenylation enzymens and antibodies that recognize unique moieties of prenylated proteins, which unique moieties are transferred from the unnatural substrates are used for detecting and isolating prenylated proteins, and for screening for inhibitors of prenylation enzymes.Type: GrantFiled: July 21, 2006Date of Patent: June 29, 2010Assignee: University of Kentucky Research FoundationInventors: Hans Peter Spielmann, Douglas A. Andres
-
Publication number: 20100143364Abstract: The invention relates to antibodies, including chimeric monoclonal antibodies, and fragments thereof, that bind to cocaine. The invention also relates to the use of these or any anti-cocaine antibodies, derivatives or variants in the prevention or treatment of cocaine-related disorders and in the amelioration of one or more symptoms associated with a cocaine-related disorder.Type: ApplicationFiled: December 5, 2008Publication date: June 10, 2010Applicant: Vybion, Inc.Inventors: Lee A. Henderson, John D. Noti, Wallace R. Fish, Brian Miller
-
Publication number: 20100125130Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of fibrin deposition in the tumour and induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells, tumour regression, cytotoxicity and receptor binding activities of the TNF on tumour cells are unaffected. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: ApplicationFiled: September 10, 2009Publication date: May 20, 2010Inventors: Deborah Ann RATHJEN, Roger Aston
-
Publication number: 20100112601Abstract: The present invention provides an anti-PAC1 monoclonal antibody capable of recognizing a PAC1 having a native structure, a PAC1 activity regulator (in particular, activity inhibitor) containing the antibody, a prophylactic/therapeutic agent for a disease associated with accentuation of a bioactivity of PAC1, containing the antibody, a diagnostic reagent for a disease associated with an abnormality of PAC1 activity, containing the antibody, and a screening method for a substance that regulates the expression of PAC1, using the antibody and a PAC1-expressing cell.Type: ApplicationFiled: August 7, 2007Publication date: May 6, 2010Applicants: Kyoto University, Takeda Pharmacetical Company LimitedInventors: Masahiro Shirakawa, Hiroshi Inooka
-
Publication number: 20100062542Abstract: It is intended to detect, concentrate and purify aflatoxins of all types which are possibly contained in a sample such as a food. It is also intended to detect the total amount or the individual amounts thereof at a high sensitivity. By using aflatoxin B2 or its derivative as a hapten compound, an antibody, which shows the same reactivity to individual aflatoxin analogs and is highly tolerant to organic solvents, is obtained. Then, a detection/concentration/purification means and an immunological detection means with the use of the above antibody are constructed. The detection means thus constructed achieves a high sensitivity and excellent quantification properties.Type: ApplicationFiled: November 13, 2007Publication date: March 11, 2010Inventors: Mikiko Uchigashima, Shiro Miyake, Hiroshi Yamashita
-
Publication number: 20100031377Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.Type: ApplicationFiled: August 9, 2005Publication date: February 4, 2010Applicant: ELAN PHARMACEUTICALS, INC.Inventors: Dale B Schenk, Eliezer Masliah, Manuel J. Buttini, Tamie J. Chilcote, Edward Rockenstein, Kate Dora Games
-
Publication number: 20100028901Abstract: The invention relates to the use of at least one of the following Formula (I) compounds: wherein n=1, Ra notably represents —COOH, Rb notably represents —CH3—, Z notably represents —CH2—CHOH—, wherein the compound may be in the form of salts or, if at least one asymmetric carbon atom is present, in the form of isolated isomers or as a racemic mixture, as a physiological marker for carrying out a method for the in vitro or ex vivo diagnosis of psychiatric disorders and/or intestinal dysbioses.Type: ApplicationFiled: April 13, 2007Publication date: February 4, 2010Applicant: AUREInventors: Celine Chery, Emmanuelle Lefebvre, Marc Merten
-
Patent number: 7655429Abstract: Topiramate analogs have substituents at the sulfamate group, 9-position, or 10-position. Topiramate analogs may include immunogenic moieties to prepare anti-topiramate antibodies, or antigenic moieties for immunodiagnostic assays. Also, the topiramate analog can include tracer moieties for detecting the presence or amount of the analog during an immunodiagnostic assay. Additionally, the topiramate analogs can be used in immunodiagnostic assays to compete with topiramate for binding with anti-topiramate antibodies. Such an immunodiagnostic assay can be used for detecting the presence of topiramate in a sample obtained from a subject previously administered topiramate by the following: combining an anti-topiramate antibody and a topiramate analog with a sample to form a first composition; allowing any free topiramate from the sample and the topiramate analog to compete for binding with the antibody; detecting binding between the topiramate analog and the antibody.Type: GrantFiled: September 20, 2007Date of Patent: February 2, 2010Assignee: Seradyn, Inc.Inventors: Anlong Ouyang, Lili Arabshahi
-
Patent number: 7649085Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.Type: GrantFiled: May 26, 2006Date of Patent: January 19, 2010Assignee: Roche Diagnostics Operations, Inc.Inventors: Gerald F. Sigler, Raymond A. Hui, Ina Deras, Richard Terry Root, Erasmus Huber, Herbert W. Von Der Eltz
-
Patent number: 7638291Abstract: Generally, the present invention relates to topiramate analogs that have substituents at the sulfamate group or at the 9-position or 10-position. The topiramate analogs can include immunogenic moieties that can be used to prepare anti-topiramate antibodies, or antigenic moieties that can be used in immunodiagnostic assays for topiramate. Also, the topiramate analog can include tracer moieties for detecting the presence or amount of the analog during an immunodiagnostic assay. Additionally, the topiramate analogs can be used in immunodiagnostic assays to compete with topiramate for binding with anti-topiramate antibodies.Type: GrantFiled: October 20, 2005Date of Patent: December 29, 2009Assignee: Seradyn, Inc.Inventors: Anlong Ouyang, Lili Arabshahi
-
Publication number: 20090304710Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38.Type: ApplicationFiled: October 16, 2007Publication date: December 10, 2009Applicant: SANOFI-AVENTISInventors: Peter U. Park, Laura M. Bartle, Anna Skaletskaya, Viktor Golmakher, Daniel Tavares, Jutta Deckert, Vincent Mikol, Veronique Blanc
-
Publication number: 20090297511Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide, active fragments thereof or an antibody thereto.Type: ApplicationFiled: December 4, 2008Publication date: December 3, 2009Applicant: Neuralab LimitedInventor: Dale B. Schenk
-
Publication number: 20090285824Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: ApplicationFiled: December 20, 2005Publication date: November 19, 2009Applicant: AMGEN INC.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20090280128Abstract: An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFN?. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFN?.Type: ApplicationFiled: December 20, 2006Publication date: November 12, 2009Inventors: Yumiko Kamogawa, Minkwon Cho, Naoko Arai, Koji Ishida
-
Publication number: 20090263879Abstract: This invention pertains to a method for detecting a compound in the presence of other compounds that are substantially similar in structure and metabolically related to the analyte. The invention is particularly suited for the detection of S-adenosylmethionine in the presence of S-adenosylhomocysteine, other nucleosides and derivatives in a biological sample. The methods of this invention involve an antibody produced specifically against S-adenosylmethionine; particularly, analogs modified strategically at the sulfonium position. An assay protocol comprises chemically modified analyte analog linked to an enzymatic reporter and the aforementioned antibody was used to demonstrate the assay specificity and sensitivity. Additional assay method with immobilized immunogen, the specific antibody, and an enzyme labeled secondary antibody was also described for illustration. The invention also features hapten design and novel compounds used as haptens to prepare immunogen and for the specific antibody production.Type: ApplicationFiled: April 17, 2009Publication date: October 22, 2009Inventors: Chiu Chin Chang, Chan-Sui Pang
-
Patent number: 7598352Abstract: A method of identifying a polypeptide monobody having target protein binding activity, said method comprising: providing a host cell comprising (i) a reporter gene under control of a 5? regulatory region operable in the host cell, (ii) a first chimeric gene which encodes a first fusion polypeptide comprising a target protein, or fragment thereof, fused to a C-terminus of a DNA-binding domain which binds to the 5? regulatory region of the reporter gene, and (iii) a second chimeric gene which encodes a second fusion polypeptide comprising a polypeptide monobody fused to a transcriptional activation domain; and detecting expression of the reporter gene, which indicates binding of the polypeptide monobody of the second fusion polypeptide to the target protein such that the transcriptional activation domain of the second fusion polypeptide is in sufficient proximity to the DNA-binding domain of the first fusion polypeptide to allow expression of the reporter gene.Type: GrantFiled: November 19, 2001Date of Patent: October 6, 2009Assignee: University of RochesterInventor: Shohei Koide
-
Publication number: 20090221066Abstract: The present invention provides a method of preparing an anti-methylated DNA antibody, comprising a step of administering to an animal an oligodeoxyribonucleotide containing a methylated cytosine(s) and an oligodeoxyribonucleotide containing no methylated cytosine. The antibody prepared by this method is capable of detecting a DNA containing a methylated cytosine(s) in a state close to the state of a biological component.Type: ApplicationFiled: March 27, 2007Publication date: September 3, 2009Inventors: Kunio Shiota, Shintaro Yagi, Fumiko Sunaga, Keiji Hirabayashi
-
Publication number: 20090214565Abstract: The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFN?”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFN? protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFN? subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFN? related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.Type: ApplicationFiled: February 6, 2009Publication date: August 27, 2009Inventors: Jacques BANCHEREAU, Kiley Prilliman, Virginia Pascual, Anna Karolina Palucka
-
Patent number: 7569678Abstract: Activated haptens useful for generating immunogens to HIV protease inhibitors, immunogens useful for producing antibodies to HIV protease inhibitors, and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central, non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir, nelfinavir, amprenavir, ritonavir, and indinavir, and a murine hybridoma producing said antibodies.Type: GrantFiled: January 31, 2007Date of Patent: August 4, 2009Assignee: Roche Diagnostics Operations, Inc.Inventors: Gerald F. Sigler, Raymond A. Hui, Ina Deras, Erasmus Huber, Herbert W. Von Der Eltz, Sigrun Metz, Peter Kern
-
Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs
Patent number: 7569676Abstract: The present invention comprises novel analogs of ecstasy-class compounds and novel ecstasy-class immunogens leashed out of, i.e., derived from, the methylenedioxy position. The invention also comprises unique monoclonal antibodies generated using MDO-leashed MDMA immunogens as well as unique conjugates and tracers. These antibodies, conjugates, and tracers are useful in immunoassays for the detection of ecstasy-class compounds in biological fluids.Type: GrantFiled: March 9, 2005Date of Patent: August 4, 2009Assignee: Roche Diagnostics Operations, Inc.Inventors: Mitali Ghoshal, Gerald F. Sigler, Richard Terry Root, Anlonga Ouyang, Salvatore J. Salamone -
Publication number: 20090130095Abstract: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.Type: ApplicationFiled: March 17, 2008Publication date: May 21, 2009Applicant: Novartis Vaccines & Diagnostics, Inc.Inventors: Mark de Boer, Leah B. Conroy
-
Patent number: 7504106Abstract: A method for treating patients with renal failure includes administering to them an effective amount of antibody or of a functional equivalent thereof to at least two of urea, creatinine, tumor necrosis factor alpha, interferon gamma, interleukin 6 and interleukin 1 beta. Soluble cytokine receptors also can be employed. The method can be used as a supplement to or as partial or complete replacement for dialysis. A pharmaceutical composition includes antibody or functional equivalent thereof to urea, creatinine, or both; antibody, functional equivalent or soluble cytokine receptor to tumor necrosis factor alpha, interferon gamma, interleukin 6, interleukin 1 beta or any combination thereof The composition can be included in a kit.Type: GrantFiled: March 14, 2006Date of Patent: March 17, 2009Inventors: Boris Skurkovich, Ellen Millstein, Simon Skurkovich